2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Phase 2/3
1
Status
Terminated
2
Unknown
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Observational
5
Interventional
3
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
10180
Neoplasms
7807
Carcinoma, Non-Small-Cell Lung
5756
Prostatic Neoplasms
5024
Colorectal Neoplasms
4603
Lung Neoplasms
3723
Leukemia, Myeloid, Acute
3102
Neoplasm Metastasis
3082
Multiple Myeloma
3081
Pancreatic Neoplasms
2843
Melanoma
2651
Ovarian Neoplasms
2573
Lymphoma
2570
Carcinoma, Hepatocellular
2479
Stomach Neoplasms
2329
Recurrence
2229
Head and Neck Neoplasms
2102
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2086
Lymphoma, Non-Hodgkin
2057
Leukemia
2013
Brain Neoplasms
1902
Glioblastoma
1795
Colonic Neoplasms
1790
Leukemia, Lymphocytic, Chronic, B-Cell
1771
Rectal Neoplasms
1719
Uterine Cervical Neoplasms
1693
Squamous Cell Carcinoma of Head and Neck
1654
Lymphoma, Follicular
1651
Lymphoma, Large B-Cell, Diffuse
1597
Carcinoma, Renal Cell
1577
Interventions
salicylhydroxamic acid
1
brolucizumab
1
aflibercept
1
Triamcinolone Acetonide
1
Ranibizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Interventional
×
Macular Degeneration
×
Clear all
NCT02626377
2023-10-23
ICE
Centre Hospitalier Universitaire de Besancon
Phase NA
Terminated
186 enrolled
NCT03710564
2023-01-30
MERLIN
Novartis
Phase 3
Terminated
535 enrolled
14 charts
NCT00811200
2009-07-02
TORR
Leiden University Medical Center
Phase 2/3
Unknown
220 enrolled